Title : Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Pub. Date : 2010 May 1

PMID : 20351323






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PURPOSE: Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) used in a vast range of cancers. Sunitinib kinase insert domain receptor Homo sapiens
2 PURPOSE: Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) used in a vast range of cancers. Sunitinib kinase insert domain receptor Homo sapiens
3 CONCLUSION: Treatment with VEGFR TKIs sunitinib and sorafenib is associated with a significant increase in the risk of ATEs. Sunitinib kinase insert domain receptor Homo sapiens